|

Mass General to Study Psilocybin at New Psychedelic Research Center

Mass General to Study Psilocybin
Photo by CDC on Unsplash

Massachusetts General Hospital has launched a new Center for Neuroscience of Psychedelics to better understand how psychedelic therapies can be used to treat depression, anxiety, post-traumatic stress disorder (PTSD), and other mental health conditions. The center is a collaborative effort between Mass General’s Department of Psychiatry, the Department of Radiology’s Athinoula A. Martinos Center for Biomedical Imaging, and the Center for Genomic Medicine’s Chemical Neurobiology Laboratory. 

“In the last couple decades, the possibility of using psychedelics for treatment of psychiatric illness has seen a renaissance, and the evidence so far is compelling enough to warrant investigation of their potential and their effects on the brain,” says Sharmin Ghaznavi, MD, PhD, associate director for the Center for Neuroscience of Psychedelics. “We are focused on understanding how psychedelics impact the brain, from neurons to networks, to bring about the kind of change that provides meaningful and sustained relief for our patients suffering with mental illness.” 

Half of all Americans will experience mental illness in their lifetime, yet, many do not improve with standard therapy. Researchers believe that, for some, the brain is less capable of change in ways that improve mental health. Emerging research suggests that psychedelics have the potential to improve the brain’s neuroplasticity that makes healing possible. 

One of the Center for Neuroscience of Psychedelics’ first research projects will focus on how psilocybin, the naturally occurring psychedelic medicine produced by hallucinogenic mushrooms, affects brain circuits in patients with treatment-resistant depression. Psilocybin is a Schedule 1 substance under the Controlled Substance Act of 1970. But recent studies have shown the hallucinogen to significantly reduce symptoms of depression when combined with guided psychotherapy. 

Similar Posts

  • 4 NEW Psychedelics Trial Updates in 1 Day | Psilocybin, LSD, 18MC + Microdosing [MNMD, CMPS, FH]

    Whether or not psychedelic medicines will become legalized to treat patients with mental health conditions will ultimately rest on whether clinical trials treating conditions with compounds like psilocybin are successful.

    This is why today’s news is so exciting. We got updates on four separate clinical trials.
    First, is new data from a phase 1 clinical trial using Compass Pathways (Nasdaq: CMPS) Comp360 psilocybin. This trial added to the growing data showing that large doses of psilocybin are safe to take. It also showed no negative cognitive side effects of taking the drug.

    Next, we got updates on two MindMed (Nasdaq: MNMD, NEO: MMED) trials. First, we found out about a new phase 1 trial which will combine LSD with SSRIs. This will be important, because we need to know whether mental health patients with disorders like major depressive disorder can remain on their prescriptions when undergoing psychedelic therapy.

    Next, MindMed announced that their phase 1 clinical trial attempting to treat addiction with 18-MC, a proprietary non-hallucinogenic version of ibogaine, was completed. We should expect data relatively soon, and a phase 2a trial to begin shortly after.

    Finally, we learned of a new microdosing trial that is set to begin at the University of Toronto. This phase 2 trial will test treating persistent depressive disorder using psilocybin microdoses. The psilocybin is Filament Health’s (OTCQB:FLHLF, NEO:FH) version of psilocybin, making it an important step for this company.

    For investors in psychedelic stocks, and those who just want to see better mental health care treatments alike, this was a big week. Hopefully, as time progresses, we will start getting data back from these trials and the shroom boom will go into full force!

    Can psychedelics treat mental health conditions? Can microdosing help depression? Can you keep taking antidepressants while taking LSD? Today, we became a step closer to answering all of these questions!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy
    @Psychedelic Spotlight

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Microdosing #Psilocybin